EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

Hydroxysteroid 17β‐dehydrogenase 13 ( Hsd17b13 ) knockdown attenuates liver steatosis in high‐fat diet obese mice

Shehroz Mahmood, Nicola Morrice, Dawn Thompson, Sara Milanizadeh, Sophie Wilson, Philip D Whitfield, George D Mcilroy, Justin J Rochford, Nimesh Mody

Experimental Physiology · 2025

DOI: 10.1113/ep092535 ↗

At a glance

Journal article in Experimental Physiology, 2025. Written by Shehroz Mahmood and 8 co-authors. Institution: Aberdeen Cardiovascular & Diabetes Centre, School of Medicine, Medical Sciences & Nutrition , University of Aberdeen, Aberdeen, UK. Major MEDLINE topics: Fatty Liver, 17-Hydroxysteroid Dehydrogenases. Cited 13 times so far (Crossref); 50 references. The full text is freely available (open access, CC BY 4.0). Funded by: Wellcome Trust ISSF international partnership award, British Heart Foundation, Wellcome Trust ISSF small project.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Hydroxysteroid 17β‐dehydrogenase 13 (HSD17B13) loss‐of‐function gene variants are associated with a decreased risk of metabolic dysfunction‐associated steatotic liver disease (MASLD). Our RNA‐seq analysis of steatotic liver from obese mice ± fenretinide treatment identified major beneficial effects of fenretinide on expression of hepatic genes including Hsd17b13 . We sought to determine the relationship between Hsd17b13 expression and MASLD and to validate it as a therapeutic target by liver‐specific knockdown. Hsd17b13 expression, which is unique to hepatocytes and associated with the lipid droplet, was elevated in multiple models of MASLD and normalised with the prevention of obesity and steatotic liver. Direct, liver‐specific, shRNA‐mediated knockdown of Hsd17b13 ( shHsd17b13 ) in high‐fat diet (HFD)‐obese mice, markedly improved hepatic steatosis with no effect on body weight, adiposity or glycaemia. shHsd17b13 decreased elevated serum alanine aminotransferase (ALT), serum fibroblast growth factor 21 (FGF21) levels, and markers of liver fibrosis, for example, expression of Timp2 . shHsd17b13 knockdown in HFD‐obese mice and Hsd17b13 overexpression in cells reciprocally regulated expression of lipid metabolism genes, for example, Cd36 . Global lipidomic analysis of liver tissue revealed a major decrease in diacylglycerols (e.g. DAG 34:3) with shHsd17b13 expression and an increase in phosphatidylcholines containing polyunsaturated fatty acids (PUFA) for example, phosphatidylcholine (PC) 34:3 and PC 42:10. Expression of key genes involved in phospholipid and PUFA metabolism, for example, Cept1 , was also reciprocally regulated suggesting a potential mechanism of Hsd17b13 biological function and role in MASLD. In conclusion, Hsd17b13 knockdown in HFD‐obese adult mice was able to alleviate MASLD via regulation of fatty acid and phospholipid metabolism, thereby confirming HSD17B13 as a genuine therapeutic target for MASLD and the development of liver fibrosis.

Subjects

MeSH terms (MEDLINE)

Fatty Liver17-Hydroxysteroid DehydrogenasesGene Knockdown TechniquesDiet, High-FatAnimalsMiceMice, ObeseFatty AcidsPhospholipidsLoss of Function MutationLiverAlanine TransaminaseFibroblast Growth FactorsPhosphatidylcholinesMaleMice, Inbred C57BLRNA-Seq

Author keywords

fenretinidefibrosishydroxysteroid 17β‐dehydrogenase 13 (Hsd17b13)metabolic dysfunction‐associated steatotic liver disease (MASLD)phospholipids

Substances

17beta-hydroxysteroid dehydrogenase type 13, mouse17-Hydroxysteroid DehydrogenasesFatty AcidsPhospholipidsfibroblast growth factor 21Alanine TransaminaseFibroblast Growth FactorsPhosphatidylcholines

Authors and institutions

  • Aberdeen Cardiovascular & Diabetes Centre, School of Medicine, Medical Sciences & Nutrition , University of Aberdeen, Aberdeen, UK.
  • Institute of Medical Sciences, School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Aberdeen, UK.
  • Centre for Genome Enabled Biology & Medicine, University of Aberdeen, Aberdeen, UK.
  • Glasgow Polyomics, University of Glasgow, Glasgow, UK.
  • The Rowett Institute, School of Medicine, Medical Sciences & Nutrition, University of Aberdeen, Aberdeen, UK.

Funding

  • Wellcome Trust ISSF international partnership award
  • British Heart Foundation
  • Wellcome Trust ISSF small project
  • Wellcome Trust
  • James Mearns Trust PhD studentship
  • University of Aberdeen CGEBM PhD studentship

Cite

APA

Mahmood, S., Morrice, N., Thompson, D., Milanizadeh, S., Wilson, S., Whitfield, P. D., Mcilroy, G. D., Rochford, J. J., & Mody, N. (2025). Hydroxysteroid 17β‐dehydrogenase 13 ( Hsd17b13 ) knockdown attenuates liver steatosis in high‐fat diet obese mice. Experimental Physiology. https://doi.org/10.1113/ep092535

Vancouver

Mahmood S, Morrice N, Thompson D, Milanizadeh S, Wilson S, Whitfield PD, et al. Hydroxysteroid 17β‐dehydrogenase 13 ( Hsd17b13 ) knockdown attenuates liver steatosis in high‐fat diet obese mice. Experimental Physiology. 2025. doi:10.1113/ep092535

BibTeX
@article{Mahmood2025,
  author = {Mahmood, Shehroz and Morrice, Nicola and Thompson, Dawn and Milanizadeh, Sara and Wilson, Sophie and Whitfield, Philip D and Mcilroy, George D and Rochford, Justin J and Mody, Nimesh},
  title = {Hydroxysteroid 17β‐dehydrogenase 13 ( Hsd17b13 ) knockdown attenuates liver steatosis in high‐fat diet obese mice},
  journal = {Experimental Physiology},
  year = {2025},
  doi = {10.1113/ep092535}
}
Start for free →